Page 35 - Recursion Pharmaceuticals News Today

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) shares fell 3.9% during trading on Friday after an insider sold shares in the company. The stock traded as low as $8.35 and last traded at $8.43. 724,610 shares were traded during mid-day trading, a decline of 49% from the average session volume of 1,433,050 shares. The stock […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $8.79, for a total transaction of $78,099.15. Following the transaction, the director now owns 7,540,747 shares in the company, valued at […]

It's competing in a soon-to-be hotly contested space.

BioPharma

Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) in a report issued on Monday morning, The Fly reports. The brokerage issued an equal weight rating and a $8.00 target price on the stock. A number of other equities research analysts have also weighed in on RXRX. Needham & Company LLC […]

Recursion Pharma (RXRX) shares jumped for the second straight session on Tuesday to double its value this month amid interest in AI led drug discovery. Read more here.

Equities Research Analysts’ new coverage for Monday, May 22nd: StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ). They issued a sell rating on the stock. StockNews.com started coverage on shares of Airgain (NASDAQ:AIRG). The firm issued a buy rating on the stock. StockNews.com began coverage on shares of Alpha Pro Tech (NYSE:APT). StockNews.com […]

New opportunities are becoming apparent, but so are fresh risks in the biotech field.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $5.09, for a total value of $45,224.65. Following the sale, the director now owns 7,549,632 shares in the company, valued at approximately $38,427,626.88. […]

CHICAGO – The Huntington Disease Health Index was an accurate, clinically meaningful tool for participants in the KINECT-HD trial to report symptomatic disease burden changes when treated with valbenazine, according to a recent study.“The Huntington Disease Health Index is a disease-specific, patient-reported outcome measure [that] was designed to measure clinically meaningful changes